Fentanyl Administered Intraorally for Rapid Treatment of Orthopedic Pain (FAIRTOP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00685295
Recruitment Status : Completed
First Posted : May 28, 2008
Results First Posted : February 9, 2017
Last Update Posted : February 9, 2017
Information provided by (Responsible Party):
Stephen H. Thomas, MD MPH, Massachusetts General Hospital

Brief Summary:
Assess whether transbuccal fentanyl provides more rapid relief of orthopedic pain, than does the comparator Percocet

Condition or disease Intervention/treatment Phase
Pain, Fracture, Sprain Drug: Fentanyl Drug: Lansoprazole Drug: Oxycodone Phase 1 Phase 2

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Fentanyl Administered Intraorally for Rapid Treatment of Orthopedic Pain in the ED
Study Start Date : August 2008
Actual Primary Completion Date : February 2009
Actual Study Completion Date : February 2009

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Arm 1 / Fentora

Intervention Group:

Subject receives:

  1. placebo oral/swallowed pill
  2. Fentanyl (Fentora) 100mcg rapidly dissolving transbuccal tablet
Drug: Fentanyl
Fentanyl rapid dissolving tablet 100mcg
Other Name: Fentora

Active Comparator: Arm 2 / Percocet/Prevacid

Active Comparator Group:

Subject receives:

  1. Oxycodone/APAP (Percocet) 5/325 mg oral/swallowed pill
  2. Lansoprazole 15 mg (Prevacid) comparator rapidly dissolving transbuccal tablet
Drug: Lansoprazole
lansoprazole 15mg rapidly dissolving tablet
Other Name: Prevacid SoluTab

Drug: Oxycodone
Oxycodone 5/325 mg tablet
Other Name: Percocet

Primary Outcome Measures :
  1. Time to Analgesia [ Time Frame: 60 minutes ]
    Time it took for subjects to achieve a pain score reduction of 2 units (on a 0 to 10 scale)

  2. Pain Reduction [ Time Frame: 60 minutes ]
    Number of subjects who reached pain reduction. A subject was deemed to have reached pain reduction if there was a two-point drop in pain scale (0-10).

Secondary Outcome Measures :
  1. Occurrence of Untoward Opioid Side Effects [ Time Frame: 120 minutes ]
    Subjects were monitored for any signs of untoward opioid side effects.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • 18-60 years of age
  • Present to ED with a chief complaint of extremity injury
  • Negative pregnancy test (urine or blood)
  • Clinician judges subject to need extremity radiography to rule out a fracture
  • Subjects must indicate that their pain is of sufficient severity to warrant treatment with a pain medication stronger than acetaminophen or aspirin.
  • Subject's treating ED provider is aware of, and approves, participation (i.e. participation cannot be allowed to impair provision of standard patient care).


  • Treating provider judges that IV analgesia is required
  • Allergy to acetaminophen or to any opiate/opioid
  • Currently taking phenothiazines or CNS depressants (including alcohol), or if subject has taken MAO inhibitors or SSRIs within the past two weeks
  • Already taken or been administered opioid analgesia for their current injury
  • Chronic opioid therapy or if the subject (or their medical records) indicate a history of opioid abuse
  • Breastfeeding mothers
  • If subject is planning to drive home after their ED visit, or if they are judged for any other reason to be non-candidates for opioid therapy.
  • hypersensitivity to lansoprazole
  • phenylketonuria

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00685295

United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Massachusetts General Hospital
Principal Investigator: Stephen H Thomas, MD, MPH Massachusetts General Hospital

Responsible Party: Stephen H. Thomas, MD MPH, Attending Physician, Massachusetts General Hospital Identifier: NCT00685295     History of Changes
Other Study ID Numbers: FAIRTOP
First Posted: May 28, 2008    Key Record Dates
Results First Posted: February 9, 2017
Last Update Posted: February 9, 2017
Last Verified: December 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: There is no plan to make individual participant data available to other researchers.

Keywords provided by Stephen H. Thomas, MD MPH, Massachusetts General Hospital:
Emergency Department

Additional relevant MeSH terms:
Fractures, Avulsion
Fractures, Bone
Wounds and Injuries
Acetaminophen, hydrocodone drug combination
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Adjuvants, Anesthesia
Anesthetics, Intravenous
Anesthetics, General
Anti-Ulcer Agents
Gastrointestinal Agents
Proton Pump Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Antirheumatic Agents